IONS Looks 26.4% Overvalued on GF Value™
Ionis Pharmaceuticals (NASDAQ: IONS) is considered 26.4% overvalued according to GuruFocus's GF Value™ metric, trading at $60.80 per share against an intrinsic value of $48.09. The company's Price-to-Sales ratio of 11.38 is above its historical median, suggesting high investor expectations for future revenue growth despite its current unprofitability. Ionis holds a moderate GF Score™ of 70/100, indicating strong growth but weaknesses in profitability and financial strength, with a notable net selling trend from insiders.
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
Ionis Pharmaceuticals (Nasdaq: IONS) announced it will present new data on severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026. The presentations will include one-year data for TRYNGOLZA® (olezarsen), recently approved in the U.S. for sHTG, and Phase 1 data for ION775, a next-generation investigational siRNA. These presentations aim to reinforce Ionis' leadership and commitment to advancing treatments for sHTG, a condition that poses a risk of life-threatening acute pancreatitis.
Eagle Health Investments LP Acquires New Position in Ionis Pharmaceuticals, Inc. $IONS
Eagle Health Investments LP has acquired a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), purchasing 194,577 shares valued at approximately $15.4 million, making it 2.6% of their portfolio. Despite significant insider selling totaling $18.3 million over the past 90 days, analysts maintain a "Moderate Buy" rating with a consensus price target of $94.15. The company's stock opened at $60.80, and while quarterly revenue decreased year-over-year, its adjusted loss was narrower than anticipated.
Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS
Great Lakes Advisors LLC has acquired 66,924 shares of Ionis Pharmaceuticals (NASDAQ:IONS) in the second quarter, valued at approximately $5.3 million. This comes as institutional investors and hedge funds own 93.86% of IONS, despite company insiders selling over $18 million worth of shares. Ionis Pharmaceuticals reported strong quarterly revenue of $267.95 million, beating analyst estimates, but its revenue was down 40.7% year-over-year.
Edmond DE Rothschild Holding S.A. Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS
Edmond DE Rothschild Holding S.A. has acquired a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), purchasing 113,320 shares valued at approximately $8,985,000 during the second quarter. This move comes as other institutional investors have also adjusted their positions in the company, and insiders have recently sold significant amounts of stock. Analysts currently hold a "Moderate Buy" consensus rating for Ionis Pharmaceuticals with a target price of $94.15.
Why Is Ionis Pharmaceuticals (IONS) Pushing RG-6299 Into A Pivotal Phase III Trial?
Ionis Pharmaceuticals, in collaboration with Roche and Chugai, is advancing RG-6299, an antisense therapy for IgA nephropathy, into a global Phase III trial. This move targets an unmet medical need and aligns with Ionis' strategy of leveraging its RNA platform through partnerships for late-stage drug development. Successful trial results could lead to regulatory filings and commercialization, reinforcing Ionis' revenue and margin growth narrative.
TimesSquare Capital Management LLC Takes $48.69 Million Position in Ionis Pharmaceuticals, Inc. $IONS
TimesSquare Capital Management LLC has acquired a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), purchasing 614,070 shares valued at $48.69 million, making it a 0.37% owner of the company. Other institutional investors also adjusted their holdings in Ionis, which saw its stock open at $58.63 with a market cap of $9.74 billion. Despite a consensus "Moderate Buy" rating from analysts with an average price target of $94.65, the company reported a year-over-year revenue decline of 40.7% and remains unprofitable, though it beat quarterly earnings estimates.
Grandfield & Dodd LLC Invests $2.94 Million in Ionis Pharmaceuticals, Inc. $IONS
Grandfield & Dodd LLC recently invested $2.94 million in Ionis Pharmaceuticals, acquiring 37,077 shares. Institutional investors collectively own a significant 93.86% of the company, and analysts maintain a "Moderate Buy" rating despite some recent target reductions. The company surpassed Q2 revenue and EPS expectations, though insiders have sold a notable amount of stock recently.
Familial Amyloid Polyneuropathy Market
The global Familial Amyloid Polyneuropathy (FAP) market is projected to reach USD 5.8 billion by 2036, growing from USD 2.2 billion in 2026, at a CAGR of 10.2%. This growth is primarily driven by the increasing adoption of disease-modifying therapies, with gene silencing therapies estimated to hold a 46.0% share by therapy type in 2026. Key players include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and AstraZeneca, focusing on various treatment approaches from RNA silencing to gene editing and oral stabilization.
Ionis Pharmaceuticals Trades at 10.9x Sales as Pipeline Optimism Clashes With Valuation Reality
Ionis Pharmaceuticals (IONS) trades at 10.9x sales, significantly higher than the 4.5x suggested by a fair ratio model, despite a 47.3% return over three years. This valuation reflects strong pipeline optimism, particularly around Tryngolza and Donidalorsen, and future late-stage readouts, with a community narrative setting fair value at $92.00. However, a Wainua trial setback and a securities investigation introduce uncertainty, prompting investors to weigh the company's ability to execute its commercial strategy against its premium valuation.
Empowered Funds LLC Increases Stock Position in Ionis Pharmaceuticals, Inc. $IONS
Empowered Funds LLC significantly increased its stake in Ionis Pharmaceuticals, Inc. during the first quarter, now holding over 103,000 shares valued at $7.75 million. Institutional investors collectively own 93.86% of the company, while insiders have sold a substantial amount of shares. Despite recent price target reductions, analysts maintain a "Moderate Buy" consensus rating for Ionis Pharmaceuticals.
ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Ionis Pharmaceuticals, Inc., providing detailed financial metrics for each fund. The ETFs are sorted by market value and include information such as weight of Ionis stock, issuer, management style, expense ratio, assets under management (AUM), price change, and 3-year NAV total return. The aim is to help investors identify diversified investment opportunities with lower risk in Ionis Pharmaceuticals through these funds.
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Handelsbanken Fonder AB
Handelsbanken Fonder AB significantly increased its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 79.1% in the second quarter, now holding 383,211 shares valued at $30.4 million. Despite institutional growth, Ionis insiders sold shares worth $18.3 million, including CEO Brett Monia's sale. Analysts maintain a "Moderate Buy" consensus with an average price target of $94.65, even after some target reductions.
(IONS) Price Dynamics and Execution-Aware Positioning
This article analyzes Ionis Pharmaceuticals Inc. (NASDAQ: IONS) price dynamics, identifying strong near-term positive sentiment that could lead to a long-term positive bias despite no clear price positioning signal and elevated downside risk. It presents three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with a multi-timeframe signal analysis to guide potential trading decisions. The report highlights key support and resistance levels across different time horizons for IONS.
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) on behalf of investors. The investigation follows Ionis's disclosure on July 9, 2026, that its Phase-3 CARDIO-TTransform trial failed to meet its primary endpoint, causing a 23.9% drop in share price. SBS is investigating claims of potential securities law violations, including false or misleading statements and failure to disclose pertinent information to investors.
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP increased its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 51.8% in the first quarter, now owning 267,215 shares valued at approximately $20.1 million. Despite this institutional buying, the company faces profitability concerns with analysts expecting continued losses. Ionis Pharmaceuticals maintains a "Moderate Buy" consensus rating from analysts, though several have recently lowered their price targets and earnings forecasts.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Pomerantz LLP is investigating potential claims on behalf of investors of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) following a significant stock drop. The investigation stems from Ionis's disclosure that its late-stage Phase-3 CARDIO-TTransform trial for Wainua, an amyloid cardiomyopathy treatment, failed to meet its primary endpoint, leading to a 23.9% decline in stock price on July 9, 2026. The firm encourages affected investors to contact them regarding possible securities fraud or unlawful business practices.
Ionis Pharmaceuticals, Inc. (IONS) Stock forecasts
Ionis Pharmaceuticals is a leading developer of antisense technology, focusing on a broad pipeline of drugs for various diseases, including cardiovascular, metabolic, neurological, and rare conditions. The article highlights early signs of commercial momentum for Tryngolza, with key catalysts approaching for the company. The current stock price is $56.56, and investors are encouraged to upgrade for detailed reports and insights.
Michael Hayden Bought 34% More Shares In Ionis Pharmaceuticals
Ionis Pharmaceuticals' Independent Director, Michael Hayden, recently purchased US$1.1m worth of stock, increasing his holding by 34%. While there was significant insider selling over the past year by the Founder, Brett Monia, this occurred at a higher price than the current stock value. Insiders collectively own 0.8% of the company, indicating some alignment with shareholder interests despite more selling than buying in the last year.
Michael Hayden Bought 34% More Shares In Ionis Pharmaceuticals
Ionis Pharmaceuticals' Independent Director, Michael Hayden, recently purchased US$1.1m worth of stock, increasing his holding by 34%. While there have been more insider sales than purchases over the past year, insiders still own 0.8% of the company, valued at US$69m, indicating some alignment with shareholder interests. The recent buying activity suggests a positive outlook from at least one key insider.
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?
Ionis Pharmaceuticals director Michael R. Hayden purchased 20,000 shares for $1.1 million, increasing his total holdings by 34%. This insider buying signals strong confidence in the company's future, especially given its focus on RNA-targeted therapies and a promising drug pipeline. The transaction comes as Ionis Pharmaceuticals, valued at $8.8 billion, continues to advance its treatments for rare genetic and neurological disorders.
ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Ionis Pharmaceuticals, Inc. (IONS). It provides a comprehensive table detailing each fund's market value, weight of IONS stock, issuer, management style, expense ratio, assets under management (AUM), price, and 3-year total return. The ETFs cover a range of investment strategies, including passive and active management, and focus on different market segments such as total market, small-cap, mid-cap, and health care.
Ionis Earnings: Early Signs of Commercial Momentum for Tryngolza as Key Catalysts Approach
Ionis reported strong second-quarter revenue of $268 million, a 56% increase year-over-year when excluding a prior one-time payment. The company reaffirmed its 2026 revenue guidance of $890 million, which includes $105 million from Tryngolza (olezarsen) net product sales. These results suggest early commercial success for Tryngolza and contribute to a positive long-term outlook for the narrow-moat company.
Narrow-Moat Ionis' Early Tryngolza Launch Makes Progress and Adds to Positive Long-Term Outlook
Ionis Pharmaceuticals is experiencing positive early commercial momentum for its drug Tryngolza, bolstering the company's long-term outlook. Despite strong competition in RNA-based therapies, Ionis has built a significant pipeline, securing its narrow economic moat. This progress comes as key catalysts approach for the company.
IONS5835891 Bond Profile — Key Metrics
This article provides key metrics for the Ionis Pharmaceuticals, Inc. 1.75% bond maturing on June 15, 2028, identified as IONS5835891. It details the issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. The bond has an outstanding amount of $575 million USD and a coupon of 1.75%.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Pomerantz LLP is investigating potential securities fraud claims against Ionis Pharmaceuticals, Inc. following a significant stock drop. The investigation began after Ionis announced that its late-stage Phase-3 CARDIO-TTransform trial for Wainua, an amyloid cardiomyopathy treatment, failed to meet its primary endpoint. This news led to Ionis's stock price falling by 23.9% on July 9, 2026.
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
Ionis Pharmaceuticals (IONS) reported a narrower-than-expected adjusted loss per share of 43 cents for Q2 2026, beating the Zacks Consensus Estimate. Quarterly revenues of $268 million also exceeded estimates, driven by commercial growth and payments from partnered programs, despite a year-over-year decline due to a large upfront payment received in the prior year. The company reaffirmed its full-year 2026 revenue and operating loss guidance, highlighting strong performance from Dawnzera and anticipated acceleration for Tryngolza sales in the second half of the year.
How Investors May Respond To Ionis Pharmaceuticals (IONS) Q2 Beat, TRYNGOLZA Launch And CSO Transition
Ionis Pharmaceuticals reported stronger-than-expected Q2 2026 results with $268 million in revenue, despite a net loss of $115 million, driven by advancing RNA-targeted programs and the launch of TRYNGOLZA. The company also announced the upcoming retirement of CSO Frank Bennett. Investors are now focused on upcoming FDA decisions for zilganersen and bepirovirsen, and how launch execution will impact the company's path to profitability.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ionis Pharmaceuticals, Inc. (IONS) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Ionis Pharmaceuticals, Inc. (IONS) following a significant drop in its stock price. This decline occurred after Ionis disclosed that its Phase-3 CARDIO-TTransform trial for the amyloid cardiomyopathy treatment Wainua did not achieve its primary endpoint. The firm is encouraging shareholders who purchased Ionis securities and are aware of relevant facts to participate in the investigation.
Ionis Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Ionis Pharmaceuticals Inc (IONS) has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters via Refinitiv, provides a brief overview of the company's financial performance. Full details are available through a TradingView subscription.
Ionis Pharmaceuticals: Q2 Earnings Snapshot
This article provides a brief snapshot of Ionis Pharmaceuticals' Q2 earnings. The content is very minimal, simply stating "Powered and protected by Privacy" and containing two image links.
IONIS PHARMACEUTICALS INC 2026: Revenue $267.95M, EPS ($0.69) — 10-Q Summary
Ionis Pharmaceuticals Inc. reported its Q1 2026 financial results, showing revenue of $267.95 million and a diluted loss per share of ($0.69). This represents a significant decrease in revenue and a shift from net income to a net loss compared to the prior year, primarily due to the lapse of 2025 upfront licensing payments. Despite this, the company achieved commercial momentum with independent launches of TRYNGOLZA and DAWNZERA and expanded its portfolio, supported by increased SG&A costs and headcount for commercialization efforts.
Ionis Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data
Ionis Pharmaceuticals (NASDAQ: IONS) currently employs 1,454 individuals worldwide as of March 2026, marking a 44.6% growth from 2023. The company, headquartered in Carlsbad, California, has a workforce primarily in the United States and is actively hiring, with 126 job postings in 2026. The average salary at Ionis Pharmaceuticals is $176,684, and the largest functional groups are Finance and Operations, Sales and Marketing, and Engineering.
Ionis Pharmaceuticals Inc (IONS) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic Advancements
Ionis Pharmaceuticals Inc (IONS) reported robust financial results for Q2 2026, with a 56% year-over-year revenue increase driven by strong product sales from TRYNGOLZA and DAWNZERA. The company also announced the FDA approval of TRYNGOLZA, its first drug for severe hypertriglyceridemia, and is making strategic advancements in its pipeline, including the anticipated launch of Zilganerse for Alexander's disease. Despite a setback in a Phase 3 study for eplontersen and anticipated increases in operating expenses, Ionis maintains a strong cash position and positive full-year revenue guidance.
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
Ionis Pharmaceuticals has announced the retirement of Dr. Frank Bennett, executive vice president and chief scientific officer, effective February 2027. Dr. Bennett, a founding scientist at Ionis, is recognized for his pivotal role in developing RNA-targeted medicines, including approved treatments for spinal muscular atrophy and ALS, transforming thousands of lives. His extensive contributions to neurological disease research and numerous drug candidates have earned him several prestigious awards throughout his distinguished career.
Transcript : Ionis Pharmaceuticals, Inc., Q2 2026 Earnings Call, Jul 29, 2026
This article is a transcript of Ionis Pharmaceuticals, Inc.'s Q2 2026 Earnings Call held on July 29, 2026. The content provides a recording of the call from S&P Capital IQ, but the full transcript is reserved for subscribers. It also includes recent news and financial data related to Ionis Pharmaceuticals, such as drug trial updates, analyst rating changes, and insider transactions.
Earnings Flash (IONS) Ionis Pharmaceuticals, Inc. Reports Q2 Revenue $268.0M, vs. FactSet Est of $189.1M
Ionis Pharmaceuticals, Inc. (IONS) announced its Q2 revenue of $268.0 million, significantly surpassing the FactSet estimate of $189.1 million. The article also provides recent news regarding the company, including clinical trial updates for Dravet Syndrome, analyst rating adjustments, and insider stock transactions.
IONS Looks 3.7% Overvalued on GF Value™ Amid Leadership Transition
Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced the upcoming retirement of its EVP and Chief Scientific Officer, Dr. Frank Bennett, with Eric Swayze, Ph.D. as his successor. The company is currently navigating a complex valuation landscape, with its stock appearing 3.7% overvalued according to GF Value, despite strong growth prospects, but also faces ongoing unprofitability and mixed investor sentiment reflected in guru activities and insider selling. Investors are advised to consider the company's innovative pipeline against its financial challenges.
Ionis Pharmaceuticals: Q2 Earnings Snapshot
This article provides a brief earnings snapshot for Ionis Pharmaceuticals (IONS) for its second quarter. While the article title suggests an earnings summary, the content itself is completely empty beyond a privacy protection notice and image links.
Ionis chief scientific officer Frank Bennett to retire
Frank Bennett, Ionis Pharmaceuticals' executive vice president and chief scientific officer, will retire in February 2027. Bennett, a founding scientist since 1989, contributed to the discovery of over 50 drug candidates and led the development of key treatments for neurological diseases. Eric Swayze, current head of research, will assume his responsibilities.
Ionis Pharmaceuticals: Q2 Earnings Snapshot
Ionis Pharmaceuticals Inc. (IONS) reported a second-quarter loss of $115 million, or 69 cents per share, which was adjusted to 43 cents per share for stock option expense. The company's revenue reached $268 million, surpassing Street forecasts of $190.7 million. This financial snapshot was generated using data from Zacks Investment Research.
Pomerantz investigates Ionis Pharmaceuticals over failed trial and stock drop.
Pomerantz LLP is investigating Ionis Pharmaceuticals and its executives for potential securities fraud. This investigation follows the failure of the Phase-3 CARDIO-TTransform trial for their drug Wainua, which led to a nearly 24% drop in Ionis's stock on July 9, 2026. The firm is encouraging affected investors to contact them regarding possible class action participation.
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS
Ionis Pharmaceuticals (IONS) experienced a significant 23% stock drop after its experimental heart disease therapy, eplontersen, failed to meet its primary efficacy endpoint in a Phase 3 trial. Hagens Berman has opened an investigation into whether Ionis was transparent enough about the trial's data and design, as a large percentage of participants were on a stabilizer that may have impacted results. Investors who suffered losses are encouraged to contact Hagens Berman.
Ionis earnings ahead: Tryngolza launch in focus amid rivalry
Ionis Pharmaceuticals is set to report Q2 earnings, with investors focused on the commercial performance of its newly launched severe hypertriglyceridemia treatment, Tryngolza. The company faces significant challenges, including a recent clinical trial setback and increasing competition from Arrowhead Pharmaceuticals, despite analysts maintaining a generally optimistic outlook with an average price target of $91.65. Key areas of investor scrutiny will be early adoption rates for Tryngolza and how Ionis plans to navigate competitive pressures and a forecasted revenue decline due to a price cut.
Lipoprotein(a) Lowering Therapies Market : Global Industry Analysis and Opportunity Assessment, 2036
The global Lipoprotein(a) Lowering Therapies Market is projected to grow from USD 946.0 million in 2026 to USD 2,198.8 million by 2036, at a CAGR of 8.8%. This growth is driven by increasing focus on advanced heart disease treatments and ongoing clinical research into therapies like antisense oligonucleotides. Key players such as Novartis, Eli Lilly, and Amgen are advancing new treatments, with antisense oligonucleotides expected to dominate the therapy type segment due to their efficacy in suppressing apolipoprotein(a) production.
Ionis Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $91.11, Implies 65% Upside
Ionis Pharmaceuticals, Inc.'s average 12-month price target has been adjusted to $91.11, down from $92.05, according to estimates from 19 analysts. This new target implies a potential upside of approximately 65% from the July 28 closing price. The consensus rating for IONS stock remains a "Buy" among 24 analysts.
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Eversept Partners LP
Eversept Partners LP significantly increased its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 17.4% in the first quarter, now owning 632,100 shares valued at $47.5 million. Despite several price target reductions from analysts, Ionis maintains a "Moderate Buy" consensus rating with an average target of $95.90. The company reported better-than-expected Q1 earnings, with revenue up 86.4% year-over-year.
Ionis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:IONS
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) reported a total revenue of $944 million USD last year. The majority of this revenue, $943.71 million USD, was generated from its RNA-targeted Medicines segment. The United States was the primary contributor to this revenue, accounting for the entire $943.71 million USD.
Ionis Pharmaceuticals, Inc. Revenue Breakdown – DUS:ISI
Ionis Pharmaceuticals, Inc. (ISI) generated €803.74 million in revenue last year, primarily from its RNA-targeted Medicines segment. The United States was the largest contributor, accounting for €803.49 million of the total revenue. This represents an increase compared to the previous year's revenue of €681.15 million.
IONS|Ionis Pharmaceuticals Inc|Price:56.550|Chg%:+0.680
Ionis Pharmaceuticals Inc. (IONS) stock is trading at $56.55, up 1.22% with a market cap of $9.35 billion. Analysts have a "Buy" rating with a target price of $89.37, indicating a 59.97% upside. The company's fundamentals are stable, growth potential is high, and institutional ownership is very high, despite recent weak market performance for the stock.
